Common Epstein-Barr virus (EBV) type-1 variant strains in both malignant and benign EBV-associated disorders. NLM AIDSLINE Important note: Information in this article was accurate in 1996. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Common Epstein-Barr virus (EBV) type-1 variant strains in both malignant and benign EBV-associated disorders.

Blood. 1996 Feb 15;87(4):1579-85. Unique Identifier : AIDSLINE MED/96190076
Schuster V; Ott G; Seidenspinner S; Kreth HW; Children's Hospital, University of Wurzburg, Germany.

Abstract: In the present study, Epstein-Barr virus (EBV) isolates from 18 malignant tumors (angioimmunoblastic lymphadenopathy [AILD], n = 4; Hodgkin's disease [HD], n = 3; pleomorphic T-cell non-Hodgkin's lymphoma [T-NHL], n = 1; B-cell non-Hodgkin's lymphoma [B-NHL], n = 8; gastric carcinoma, n = 2) as well as from 10 tonsils of EBV-seropositive children and from peripheral blood mononuclear cells of 12 children with uncomplicated infectious mononucleosis (IM) and of a boy with severe chronic active EBV infection were genotyped in the EBV nuclear antigen-2 (EBNA-2) gene. A total of 40 of 41 isolates harbored EBV type 1; in 1 specimen (tonsil), only EBV type 2 was found. Further molecular characterization of EBV type-1 wild-type isolates in the EBNA-2 gene and in the 40-kb distant EBV-encoded small RNAs (EBER) region showed that different groups of stable EBV type-1 variant strains exist in vivo both in benign and malignant lymphatic tissue. Group 1 is composed of EBV type-1 isolates (B-NHL, n = 3; T-NHL, n = 1; HD, n = 1; IM, n = 4) that showed a B95-8-like DNA sequence pattern in both viral genes. Group 2 isolates (HD, n = 1; AILD, n = B-NHL, n = 1; tonsils of EBV-seropositive children, n = 9; IM, n = 20 showed a nucleotide change at position 49095 in the EBNA-2 gene, leading to an amino acid substitution (Pro-->Ser), and EBV type-2 sequences in the EBER region. EBV type-1 isolates that fall into group 3 (AILD, n = 3; HD, n = 1; B-NHL, n = 4; gastric carcinoma, n = 2; IM, n = 6; severe chronic active EBV infection, n = 1) were characterized by typical nucleotide changes and a 3-bp insertion (CTC; extra Leu residue) in the EBNA-2 gene and an EBV type-2-specific sequence pattern in the EBER region. These EBV type-1 variant strains may represent the most prevalent circulating EBV type-1 strains in the exposed population and seem not to be restricted to a certain EBV-associated disease or tumor type. However, analysis of more EBV isolates from benign and malignant lesions must show whether more EBV type-1 substrains exist in vivo.
Keywords: Base Sequence Child DNA Primers/CHEMISTRY DNA, Viral/*GENETICS Female Genes, Structural Herpesviridae Infections/*MICROBIOLOGY Herpesvirus 4, Human/*GENETICS Human Immunoblastic Lymphadenopathy/*MICROBIOLOGY Infectious Mononucleosis/MICROBIOLOGY Lymphoma, Non-Hodgkin's/*MICROBIOLOGY Male Molecular Sequence Data Point Mutation Polymorphism, Single-Stranded Conformational RNA, Viral/GENETICS Stomach Neoplasms/*MICROBIOLOGY Support, Non-U.S. Gov't Tumor Virus Infections/*MICROBIOLOGY JOURNAL ARTICLEKWDbasesequencechilddnaprimers/chemistrydna,viral/KWDgeneticsfemalegenes,structuralherpesviridaeinfections/KWDmicrobiologyherpesvirus4,human/KWDgeneticshumanimmunoblasticlymphadenopathy/KWDmicrobiologyinfectiousmononucleosis/microbiologylymphoma,non-hodgkin's/KWDmicrobiologymalemolecularsequencedatapointmutationpolymorphism,single-strandedconformationalrna,viral/geneticsstomachneoplasms/KWDmicrobiologysupport,non-uKWDsKWDgov'ttumorvirusinfections/KWDmicrobiologyjournalarticle
960830
M9681221

Copyright © 1996 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1996. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1996. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .